期刊文献+

黑色素瘤治疗方法的研究 被引量:2

Research of melanoma treatment
下载PDF
导出
摘要 为帮助广大临床工作者对黑色素瘤治疗方法的学习,并对治疗方法存在的问题进行讨论.介绍了导致黑色素瘤发病的主要因素和临床上的常规治疗手段,并对局部切除、化疗、基因治疗和疫苗等治疗方法作重点介绍.局部切除是临床的常规治疗手段,但是预后极差,是基本的治疗手段;黑色素瘤对化疗不敏感,且化疗的有效率极低,但联合治疗方案具有一定的意义;基因治疗在临床取得应用,但无定向性,且基因转移的效率难控制;黑色素瘤疫苗是一种控制方法而不是治疗方法,在治疗黑色素瘤方面具有局限性.治疗黑色素瘤的手段较多,但是每种治疗方法都存在优势和弊端.在治疗时,根据患者的实际情况选择治疗手段尤其重要. To hhelp the majorities of clinicians learn methods of melanoma treatment and dis-cuss the treatment the cause of the main factors of melanoma incidence and clinical routine treatment was described in this article , and local excision , chemotherapy , gene therapy and vaccine therapies for highlights .Local excision is a clinical routine treatment , but the prog-nosis is poor , which is a basic mean of treatment .Melanoma is not sensitive to chemotherapy that is inefficient .But combination therapy has certain significance .Gene therapies have ob-tained clinical applications , but with no directivity , and are difficult to control the efficiency of gene transfer .Melanoma vaccine is a control method rather than therapy , and has limita-tions in the treatment of melanoma .Method of melanoma treatment is various , but each method has its advantages and disadvantages .An appropriate therapy according to the actual situation of patients is particularly important in the treatment .
出处 《哈尔滨商业大学学报(自然科学版)》 CAS 2014年第3期266-270,共5页 Journal of Harbin University of Commerce:Natural Sciences Edition
关键词 黑色素瘤 研究进展 治疗手段 melanoma research progress treatment
  • 相关文献

参考文献29

二级参考文献113

  • 1刘佳,周麟,侯梅.干扰素α在恶性黑色素瘤术后患者治疗中的研究进展[J].华西医学,2006,21(2):429-430. 被引量:3
  • 2刘勇,岑瑛,许学文,李正勇.236例皮肤恶性肿瘤临床分析[J].华西医学,2007,22(2):368-369. 被引量:15
  • 3Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J]. J Clin Oncol,2006,24( 1 ) :25 -35.
  • 4Gajewski TF, Niedzwiecki D, Johnson J, et al. Phase Ⅱ study of the farnesyltransferase inhibitor R115777 in advanced melanoma : CALGB 500104 [ J ]. J Clin Oncol, 2006,24( 18 Suppl) :8014.
  • 5Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase Ⅱ randomised discontinuation trial analysis [J]. Br J Cancer,2006,95 (5) :581 -586.
  • 6Flaherty KT, Schiller J, Schuchter LM, et al. A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel [J]. Clin Cancer Res ,2008,14 ( 15 ) : 4836 - 4842.
  • 7Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity [J]. Proc Natl Acad Sci USA, 2008,105 ( 8 ) : 3041 - 3046.
  • 8Fecher LA, Amaravadi R, Schuchter LM. Effectively targeting BRAF in melanoma: a formidable challenge [J]. Pigment Cell Melanoma Res,2008,21 (4) : 410 - 411.
  • 9Haass NK, Sproesser K, Nguyen TK, et al. The mitogenactivated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel [J]. Clin Cancer Res, 2008,14( 1 ) : 230 -239.
  • 10Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmaeokinetic and pharmaeodynamic study of the oral, small-molecule mitogen-activated protein kinase kiuase I/ 2 inhibitor AZD6244 ( ARRY-142886 ) in patients with advancedcancers [J]. J Clin Oncol,2008,26 ( 13 ) : 2139 - 2146.

共引文献40

同被引文献33

  • 1王淑瑞,齐浩,刘建强,郭伟.B16黑色素瘤移植模型的建立[J].西安文理学院学报(自然科学版),2006,9(1):18-20. 被引量:10
  • 2周伊,齐旭,肖菊香,来宝长,司履生,王一理.新型佐剂SWZY对弱免疫原性小鼠黑色素瘤瘤苗的免疫增强作用[J].细胞与分子免疫学杂志,2006,22(4):526-529. 被引量:4
  • 3周伊,齐旭,马军,来宝长,司履生,王一理.不同佐剂增强小鼠黑色素瘤瘤苗抗瘤细胞免疫效应的比较[J].肿瘤防治研究,2007,34(4):259-261. 被引量:1
  • 4Mei HF,Jin XB, Shen J, et al. 15-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the gr~wtil of implanted routine melanoma in vivo [ J ]. PloS One, 2012,7 (2) :e31328.
  • 5Eun-Young Lee, Kyong-Su Park, Yong Song Gho,et al. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis[ J ]. PIoS One ,2012,7 ( 3 ) : e33330.
  • 6Colavecchia SB, Jolly A, Mundo SL, et al. Effect of lipoarabinomannan from mycobacterium avium subsp auium in freund's incomplete adjuvant on the immune response of cattle[ J ]. Braz J Med Biol Res,2012,45(2):139-146.
  • 7Wilton DJ,Ghosh M,Chary KV,et al. Structural change in a B- DNA helix with hydrostatic pressure[ J ]. Nucleic Acids Res,2008, 36( 12 ) :4302-4307.
  • 8Granucci F, Zanoni I, Pavelka N, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation [ J ]. J Exp Med, 2004,200 (3) :287-295.
  • 9Ferrari S, Rovati B, Porta C, et al. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard or high-dose chemotherapy plus granulocyte-colony stimulating factor [ J ]. Cancer Immunol Immunother, 2003,52 (6) :359-366.
  • 10Fehniger TA, Cooper MA, Nuovn GJ, et al. CD56 bright naturalkiller cells are present in human lymph nodes and are activated by T cell-derived 1L-2 : a potential new link between adaptive and innate immunity. [ J ]. Blood ,2003,101 (8) :3052-3057.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部